<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18245">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01814410</url>
  </required_header>
  <id_info>
    <org_study_id>ER0006</org_study_id>
    <nct_id>NCT01814410</nct_id>
  </id_info>
  <brief_title>Interactive Effects of IV Ethanol and IV Nicotine</brief_title>
  <official_title>A Laboratory Study on the Interactive Effects of IV Ethanol and IV Nicotine on Subjective Effects and Cognition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>South Central VA Mental Illness Research, Education &amp; Clinical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are mixed reports on nicotine's effects on ethanol-induced impairment in cognitive
      performance and behavior in humans. The main objective of this study is to characterize the
      interactive effects of acute intravenous (IV) ethanol and nicotine administration on
      cognition and behavior in healthy smokers. The general hypothesis is that nicotine will
      attenuate the negative effects of ethanol on cognition and subjective stimulant/sedative
      effects of ethanol.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Biphasic Alcohol Effects Scale (BAES)</measure>
    <time_frame>2 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>A 14-item scale with 7 items designed to assess stimulant effects associated with the ascending limb of ethanol intoxication and 7 items developed to measure sedative effects associated with the descending limb of ethanol intoxication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scales of Mood States</measure>
    <time_frame>1 minute</time_frame>
    <safety_issue>No</safety_issue>
    <description>The following items will be assessed: high, depressed, anxious, drowsy, irritable, tired, sad, angry, nervous, nauseous, blurred vision, flushed, headache, lightheaded, dizzy, sweating, abdominal discomfort and tingling .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QSU-Brief</measure>
    <time_frame>2 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>A measure of smoking urges reflecting not only intent and desire to smoke, and anticipation of pleasure from smoking, but also anticipation of relief from negative affect and nicotine withdrawal, and urgent and overwhelming desire to smoke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digit Symbol Substitution Task</measure>
    <time_frame>2 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>A test of psychomotor performance, which measures motor persistence, sustained attention, response speed and visuomotor coordination.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>alcohol doses</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Ethanol</intervention_name>
    <arm_group_label>alcohol doses</arm_group_label>
    <other_name>Alcohol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Nicotine</intervention_name>
    <arm_group_label>alcohol doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Placebo</intervention_name>
    <arm_group_label>alcohol doses</arm_group_label>
    <other_name>Saline Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female;

          2. between the ages of 21 and 50 years;

          3. medically and neurologically healthy on the basis of history, physical examination,
             EKG, screening laboratories

          4. history of smoking daily for the past 12 months, at least 5 cigarettes daily; not
             seeking treatment for nicotine dependence

          5. social drinkers  no maximum level of alcohol consumption will be defined a priori but
             individuals who met current DSM -IV criteria for alcohol dependence (abuse will be
             allowed) will be excluded from the study.

        Exclusion Criteria:

          1. history of major medical illnesses that the physician investigator deems as
             contraindicated for the patient to be in the study;

          2. regular use of psychotropic medication (antidepressants, antipsychotics, or
             anxiolytics) and recent psychiatric diagnosis and treatment for Axis I disorders
             including major depression, bipolar affective disorder, schizophrenia or panic
             disorder;

          3. current abuse of any recreational or prescription drugs (except alcohol);

          4. alcohol na√Øve.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Ralevski, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Ralevski, Ph.D.</last_name>
    <phone>203-932-5711</phone>
    <phone_ext>4282</phone_ext>
    <email>elizabeth.ralevski@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diana Limoncelli, BA</last_name>
    <phone>203-932-5711</phone>
    <phone_ext>5217</phone_ext>
    <email>diana.limoncelli@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West Haven VA Hospital</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Ralevski, Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 14, 2014</lastchanged_date>
  <firstreceived_date>January 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Elizabeth Ralevski</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Intravenous Ethanol</keyword>
  <keyword>Intravenous Nicotine</keyword>
  <keyword>Interactive effects</keyword>
  <keyword>cognition</keyword>
  <keyword>subjective effects</keyword>
  <keyword>healthy subjects</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Nicotine polacrilex</mesh_term>
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
